Assessment of Liver Glucose Metabolism in Diabetic Subjects (CLAVA)
Primary Purpose
Newly Diagnosed Type 2 Diabetes (During the Last 12 Months)
Status
Completed
Phase
Not Applicable
Locations
Germany
Study Type
Interventional
Intervention
intravenous glucose tolerance test
hyperinsulinemic euglycemic clamp
Sponsored by

About this trial
This is an interventional basic science trial for Newly Diagnosed Type 2 Diabetes (During the Last 12 Months) focused on measuring type 2 diabetes, insulin sensitivity, hyperinsulinemic euglycemic clamp
Eligibility Criteria
Inclusion Criteria:
- newly diagnosed type 2 diabetes (during the last 12 months)or non-diabetic subjects
Exclusion Criteria:
- severe chronic diseases
- hepatitis B, C oder HIV infection
- malignancies
- immune suppressive therapy
- psychiatric illnesses
- drug or alcohol abuse
- anemia
- renal dysfunction
Sites / Locations
- German Diabetes Center
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
Botnia clamp
hyperinsulinemic euglycemic clamp
Arm Description
hyperinsulinemic euglycemic clamp following intravenous glucose tolerance test
hyperinsulinemic euglycemic clamp without previous intravenous glucose tolerance test
Outcomes
Primary Outcome Measures
M Value in hyperinsulinemic euglycemic clamp
measurement of whole body insulin sensitivity with hyperinsulinamic euglicamic clamp
Secondary Outcome Measures
Insulin-suppressed endogenous glucose production (liver insulin sensitivity)
Insulin-suppressed endogenous glucose production (liver insulin sensitivity)
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01397279
Brief Title
Assessment of Liver Glucose Metabolism in Diabetic Subjects
Acronym
CLAVA
Official Title
Assessment of Liver Glucose Metabolism in Diabetic Subjects
Study Type
Interventional
2. Study Status
Record Verification Date
June 2023
Overall Recruitment Status
Completed
Study Start Date
July 2011 (Actual)
Primary Completion Date
December 2013 (Actual)
Study Completion Date
December 2013 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
German Diabetes Center
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Type 2 diabetes is associated with hepatic insulin resistance. One consequence of insulin resistance of the liver is an altered hepatic glucose metabolism. This study investigates whether the whole body (M-value) and hepatic insulin sensitivity obtained by hyperinsulinemic euglycemic clamp is influenced by a preceding intravenous glucose tolerance test (Botnia Clamp) in subjects with type 2 diabetes.
Detailed Description
The hyperinsulinemic euglycemic clamp represents the gold standard for measuring peripheral insulin sensitivity. The insulin sensitivity is described by the M-value,which is calculated from glucose infusion rates during the last 30min of the clamp.
Glucose is metabolised in the periphery: 50% by neural tissues, 20% by splanchnic bed and liver, 15% by skeletal muscle, 5% by adipose tissue and 10% by blood cells and other tissues. Under hyperinsulinemic conditions there is a strong shift in glucose utilization: 85% skeletal muscle and 15% by neural tissues, splanchnic bed and liver, adipose tissue, blood cells and other tissues. The contribution of skeletal muscle varies with different insulin sensitivity.
We now want to investigate whether there is a difference in tissue-specific insulin sensitivity measured from a Botnia clamp (intravenous glucose tolerance test (ivGTT) and following clamp) and a single hyperinsulinemic euglycemic clamp? After a 60min ivGTT blood glucose levels in type 2 diabetic subjects are still elevated compared to baseline. High blood glucose levels can influence several parameters and may also affect insulin sensitivity. Until now, it is not proven, that the clamp preceding ivGTT does not have a significant influence on the M-value.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Newly Diagnosed Type 2 Diabetes (During the Last 12 Months)
Keywords
type 2 diabetes, insulin sensitivity, hyperinsulinemic euglycemic clamp
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
22 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Botnia clamp
Arm Type
Active Comparator
Arm Description
hyperinsulinemic euglycemic clamp following intravenous glucose tolerance test
Arm Title
hyperinsulinemic euglycemic clamp
Arm Type
Active Comparator
Arm Description
hyperinsulinemic euglycemic clamp without previous intravenous glucose tolerance test
Intervention Type
Biological
Intervention Name(s)
intravenous glucose tolerance test
Other Intervention Name(s)
ivGTT
Intervention Description
Administration of a 30% weight-adapted glucose bolus intravenously.
Intervention Type
Biological
Intervention Name(s)
hyperinsulinemic euglycemic clamp
Other Intervention Name(s)
HEC
Intervention Description
Intravenous administration of 20% glucose and insulin over 3 hours
Primary Outcome Measure Information:
Title
M Value in hyperinsulinemic euglycemic clamp
Description
measurement of whole body insulin sensitivity with hyperinsulinamic euglicamic clamp
Time Frame
3h
Secondary Outcome Measure Information:
Title
Insulin-suppressed endogenous glucose production (liver insulin sensitivity)
Description
Insulin-suppressed endogenous glucose production (liver insulin sensitivity)
Time Frame
3h
10. Eligibility
Sex
All
Minimum Age & Unit of Time
35 Years
Maximum Age & Unit of Time
69 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
newly diagnosed type 2 diabetes (during the last 12 months)or non-diabetic subjects
Exclusion Criteria:
severe chronic diseases
hepatitis B, C oder HIV infection
malignancies
immune suppressive therapy
psychiatric illnesses
drug or alcohol abuse
anemia
renal dysfunction
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Michael Roden, Prof., MD
Organizational Affiliation
Director German Diabetes Center
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Michael Roden, Prof., MD
Organizational Affiliation
Director German Diabetes Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
German Diabetes Center
City
Düsseldorf
State/Province
Nordrhein-Westfalen
ZIP/Postal Code
40225
Country
Germany
12. IPD Sharing Statement
Citations:
PubMed Identifier
25047649
Citation
Kahl S, Nowotny B, Piepel S, Nowotny PJ, Strassburger K, Herder C, Pacini G, Roden M. Estimates of insulin sensitivity from the intravenous-glucose-modified-clamp test depend on suppression of lipolysis in type 2 diabetes: a randomised controlled trial. Diabetologia. 2014 Oct;57(10):2094-102. doi: 10.1007/s00125-014-3328-3. Epub 2014 Jul 22.
Results Reference
derived
Learn more about this trial
Assessment of Liver Glucose Metabolism in Diabetic Subjects
We'll reach out to this number within 24 hrs